5Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of25 major cancers in 1990[J]. Int J Cancer,1999,80(6) :827 -841.
6Lehtinen M, Kibur M, Luostarinen T, et al. Prospects for phase Ⅲ-ⅣHPV vaccination trials in the Nordic countries and in Estonia[ ]. J Clin Virol,2000,19( 1 -2) :113 - 122.
7Monos M, Ting Y. PCR Protocols: A Guide to Methods and Application[ M ]. San Diego: Academic Press, 1990. 365 - 367.
8Dartmann K, Schwarz E, Gissmann L, et al. The nucleotide sequence and genome organization of human papillomavirus type 11 [ J ]. Virology,1986,151:124 - 130.
9Christensen ND, Reed CA, Cladel NM,et al. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6 [ J ]. Virology, 1996 ,224 ( 2 ) :477 - 486.
10Grce M, Husnjak K, Skerlev M, et al. Detection and typing of human papillomaviruses by means of polymerase chain reaction and fragment length polymorphism in male genital lesions[ J]. Anticancer Res,2000,20(3B) :2097 -2102.
1Bodily J, Laimins LA. Persistence of human papillomavirus infec- tion : keys to malignant progression [ J ]. Trends Microbiol, 2011 , 19( 1 ) :33-39.
2Franceschi S, De Vuyst H. Human papillomavirus vaccines and a- nal carcinoma[J]. Curr Opin HIV AIDS, 2009, 4( 1 ) : 57-63.
3Strauchen JA, Arya SK, Tralka TS, et al. Search for retroverus- like particles in human breast cancer cells in culture [ J ]. Cancer Res,1980,40( 11 ) : 3880-3885.
4Lichtig H, Algrisi M, Botzer LE, et al. HPV16 E6 natural variants exhibit different activities infunction alassay srelevant to the carcino genic potential of E6[ J]. Virology, 2006,350( 1 ) :216-227.
